高盛：中国医疗-生物科技引领年内估值重估；关注国内复苏拐点
Goldman Sachs·2025-06-15 16:03
15 May 2025 | 12:57AM HKT China Healthcare Pulse Biotech led valuation re-rating YTD; eyeing on inflection for domestic recovery As we note earlier (Feb 25 and Nov 24), a recovery for China healthcare is underway, with improving investor sentiment and bottoming valuation. China offshore HC saw a pickup at +21% YTD, vs MXCN +12% and is now trading at 15x, 36%tile over last 5y. The YTD strong performance of Biotech (+37%) was driven by licensing-out theme and relative resilience to geopolitical uncertainty, w ...